Microbot Medical Attracts Another Leading Physician and Expands Capabilities of its Scientific Advisory Board with Addition of Dr. Ripal Gandhi Miami-based Physician Specializes in Minimally Invasive Treatments for Perip

Medical Attracts Another Leading Physician and Expands

Capabilities of its Scientific Advisory Board with Addition of Dr. Ripal Gandhi

Physician Specializes in Minimally Invasive Treatments for

Peripheral Vascular Disease, Cancer, and Other Diseases

Mass., September 19, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific

Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that Ripal T. Gandhi, MD, FSVM, will join the

Company's robust Scientific Advisory Board (SAB). Dr. Gandhi is an interventional oncologist and a member of the Miami Cardiac

& Vascular Institute and Miami Cancer Institute physician team where he specializes in minimally invasive treatments for peripheral

vascular disease, cancer, and other diseases, and has a history of being an innovator in the Interventional Robotics field.

we announce a very exciting addition to our Scientific Advisory Board, as Dr. Gandhi is a robotic pioneer, has considerable experience

with previous generations of endovascular surgical robotics, and clearly knows the challenges they present and how our LIBERTY Robotic

System can address most, if not all of them," commented Harel Gadot, CEO, President, and Chairman."

completed over 100 robotic cases in the interventional space using larger bulky capital equipment, I was immediately drawn to the LIBERTY

technology and the barriers it breaks down," Commented Dr. Gandhi. "I am excited to bring my first-hand experience to help

guide the Microbot team's revolutionary approach to create the first ever fully disposable robotic system, which I believe will

be central in driving robotic adoption in this space."

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms

provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for

patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available

at http://www.microbotmedical.com.

to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or

prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that

contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential

products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies,

any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct the SCS's early feasibility

study which could adversely affect or delay such study, uncertainty in the results of pre-clinical and clinical trials or regulatory

pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance

of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors"

in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's

web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required